Summit Therapeutics, Inc. (SMMT)
15.47
-0.08
(-0.51%)
USD |
NASDAQ |
Oct 23, 16:00
15.48
+0.01
(+0.06%)
After-Hours: 20:00
Summit Therapeutics Enterprise Value : 11.60B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 11.60B |
| October 22, 2026 | 11.66B |
| October 21, 2026 | 11.88B |
| October 20, 2026 | 12.09B |
| October 19, 2026 | 11.68B |
| October 16, 2026 | 10.93B |
| October 15, 2026 | 11.52B |
| October 14, 2026 | 11.33B |
| October 13, 2026 | 11.64B |
| October 12, 2026 | 12.92B |
| October 09, 2026 | 13.28B |
| October 08, 2026 | 12.95B |
| October 07, 2026 | 13.57B |
| October 06, 2026 | 13.06B |
| October 05, 2026 | 13.03B |
| October 02, 2026 | 12.62B |
| October 01, 2026 | 12.57B |
| September 30, 2026 | 12.74B |
| September 29, 2026 | 12.33B |
| September 28, 2026 | 11.61B |
| September 25, 2026 | 11.71B |
| September 24, 2026 | 12.32B |
| September 23, 2026 | 12.38B |
| September 22, 2026 | 12.91B |
| September 21, 2026 | 12.73B |
| Date | Value |
|---|---|
| September 18, 2026 | 13.49B |
| September 17, 2026 | 13.38B |
| September 16, 2026 | 13.05B |
| September 15, 2026 | 13.13B |
| September 14, 2026 | 13.94B |
| September 11, 2026 | 13.25B |
| September 10, 2026 | 12.81B |
| September 09, 2026 | 13.24B |
| September 08, 2026 | 13.03B |
| September 04, 2026 | 13.29B |
| September 03, 2026 | 12.92B |
| September 02, 2026 | 10.91B |
| September 01, 2026 | 10.56B |
| August 31, 2026 | 10.13B |
| August 28, 2026 | 10.22B |
| August 27, 2026 | 10.69B |
| August 26, 2026 | 10.62B |
| August 25, 2026 | 9.925B |
| August 24, 2026 | 9.426B |
| August 21, 2026 | 9.767B |
| August 20, 2026 | 9.188B |
| August 19, 2026 | 9.727B |
| August 18, 2026 | 9.497B |
| August 17, 2026 | 9.465B |
| August 14, 2026 | 9.918B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.047M |
| Brainstorm Cell Therapeutics, Inc. | 10.42M |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | -2.080M |
| Clene, Inc. | 62.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -215.70M |
| Total Expenses (Quarterly) | 215.70M |
| EPS Diluted (Quarterly) | -0.2772 |
| Earnings Yield | -7.24% |
| Normalized Earnings Yield | -7.235 |